Enayi Onaji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Enayi Onaji has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Yusuf Jimoh
Department of Pharmaceutical and Medicinal Chemistry, Ahmadu Bello University, Zaria 810107, Nigeria
2 shared publications - Abubakar Sadiq Yakubu
Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria 810107, Kaduna State, Nigeria
1 shared publication - Apeh Lucky Junior
College of health Sciences, Ahmadu Bello University, Zaria, Nigeria
1 shared publication - Asmau Nasir Hamza
Department of Pharmaceutical and Medicinal Chemistry, Ahmadu Bello University, Zaria 810107, Nigeria
1 shared publication - Asmau Nasiru Hamza
Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria 810107, Kaduna State, Nigeria
1 shared publication - Chukwunenye Christopher Azubuike
Faculty of Pharmacy, University of Benin, Benin-City, Nigeria
1 shared publication
Latest Publications
- Open Access
- 10 November 2026
- Published by MDPI AG in Chemistry Proceedings
- Vol. 22 (1) , 151
A Computational Investigation into Chalcones and Pyrazolines Against α-Glucosidase as Potential Anti-Diabetic Agents
Diabetes mellitus is a major global public health challenge associated with significant morbidity and mortality. Although α-glucosidase inhibitors are widely used in the management of postprandial hyperglycemia, currently available drugs are often associated with undesirable side effects, reduced patient compliance, and limited therapeutic effectiveness. Consequently, there is a growing need to identify novel inhibitors with improved efficacy and safety profiles. This study aimed to investigate the potential of 14 chalcone and 4 pyrazoline compounds (18 compounds in total) as potential α-glucosidase inhibitors using computational approaches. A library of compounds was designed using ChemDraw and subjected to geometry optimization with Spartan14 software. Drug-likeness, pharmacokinetic, and toxicity properties were assessed using SwissADME and ProTox-II servers. Molecular docking studies were performed against the α-glucosidase enzyme (PDB ID: 8YIE) using AutoDock Vina to determine binding affinities and interactions within the enzyme’s active site. ADMET analysis revealed that the majority of the compounds exhibited favorable pharmacokinetic characteristics and acceptable safety profiles. Among the screened compounds, compounds PC1 and PHPY exhibited the most favorable docking scores at −9.8 kcal/mol and −9.3 kcal/mol, respectively, surpassing the reference ligand acabose (AC1) (−8.8 kcal/mol). Detailed interaction analysis revealed the formation of key hydrogen bonds, π–π stacking, and π–alkyl interactions with critical active-site residues. These findings suggest that the investigated chalcone and pyrazoline compounds may be promising candidates for further investigation as potential α-glucosidase inhibitors. However experimental enzyme inhibition assays and appropriate safety studies are necessary to validate their predicted biological activity and establish their safety profiles.
- 10 November 2026
- Published by MDPI AG in Chemistry Proceedings
- Vol. 22 (1) , 151
Open AccessA Computational Investigation into Chalcones and Pyrazolines Against α-Glucosidase as Potential Anti-Diabetic Agents
Diabetes mellitus is a major global public health challenge associated with significant morbidity and mortality. Although α-glucosidase inhibitors are widely used in the management of postprandial hyperglycemia, currently available drugs are often associated with undesirable side effects, reduced patient compliance, and limited therapeutic effectiveness. Consequently, there is a growing need to identify novel inhibitors with improved efficacy and safety profiles. This study aimed to investigate the potential of 14 chalcone and 4 pyrazoline compounds (18 compounds in total) as potential α-glucosidase inhibitors using computational approaches. A library of compounds was designed using ChemDraw and subjected to geometry optimization with Spartan14 software. Drug-likeness, pharmacokinetic, and toxicity properties were assessed using SwissADME and ProTox-II servers. Molecular docking studies were performed against the α-glucosidase enzyme (PDB ID: 8YIE) using AutoDock Vina to determine binding affinities and interactions within the enzyme’s active site. ADMET analysis revealed that the majority of the compounds exhibited favorable pharmacokinetic characteristics and acceptable safety profiles. Among the screened compounds, compounds PC1 and PHPY exhibited the most favorable docking scores at −9.8 kcal/mol and −9.3 kcal/mol, respectively, surpassing the reference ligand acabose (AC1) (−8.8 kcal/mol). Detailed interaction analysis revealed the formation of key hydrogen bonds, π–π stacking, and π–alkyl interactions with critical active-site residues. These findings suggest that the investigated chalcone and pyrazoline compounds may be promising candidates for further investigation as potential α-glucosidase inhibitors. However experimental enzyme inhibition assays and appropriate safety studies are necessary to validate their predicted biological activity and establish their safety profiles.
- Open Access
- 22 April 2026
- Published by Springer Nature in Discover Chemistry
- Vol. 3 (1) , 215
Pharmacophore based discovery of dual inhibitors targeting TOP1 and TOP2A in resistant triple negative breast cancer
Triple-negative breast cancer (TNBC) is an aggressive malignancy characterized by the absence of conventional hormonal receptors, leading to intrinsic resistance to standard therapies and poor clinical outcomes. Topoisomerase I (TOP1) and Topoisomerase II alpha (TOP2A), essential enzymes for DNA replication and transcription, have emerged as promising co-targets to overcome this therapeutic resistance. This study employed an integrated in-silico pipeline to discover novel dual-targeting inhibitors against both TOP1 and TOP2A. A structure-based pharmacophore model (AAHRR_7) was developed and rigorously validated, demonstrating high predictive power. Subsequent virtual screening of a ZINC in-trial compound library identified 475 hits, which were advanced to molecular docking against the crystal structures of TOP1 (PDB: 1T8I) and TOP2A (PDB: 4FM9). This process yielded 15 top-ranked compounds with significantly superior predicted binding affinities compared to reference inhibitors. MM/GBSA refinement and systematic ADMET profiling further prioritized two in-silico candidate molecules ZINC13740825 and ZINC00586527 which exhibited robust binding free energies and favorable drug-like properties with low predicted toxicity. Quantitative structure-activity relationship (QSAR) models and Molecular Dynamics Simulation studies confirmed their potent predicted inhibitory activity and complex stability against both targets. These findings highlight the potential of these identified compounds as promising dual TOP1/TOP2A inhibitors for TNBC therapy, offering a strategic avenue to combat resistance mechanisms. Further experimental validation is warranted to translate these computational insights into therapeutic candidates.
- 22 April 2026
- Published by Springer Nature in Discover Chemistry
- Vol. 3 (1) , 215
Open AccessPharmacophore based discovery of dual inhibitors targeting TOP1 and TOP2A in resistant triple negative breast cancer
Triple-negative breast cancer (TNBC) is an aggressive malignancy characterized by the absence of conventional hormonal receptors, leading to intrinsic resistance to standard therapies and poor clinical outcomes. Topoisomerase I (TOP1) and Topoisomerase II alpha (TOP2A), essential enzymes for DNA replication and transcription, have emerged as promising co-targets to overcome this therapeutic resistance. This study employed an integrated in-silico pipeline to discover novel dual-targeting inhibitors against both TOP1 and TOP2A. A structure-based pharmacophore model (AAHRR_7) was developed and rigorously validated, demonstrating high predictive power. Subsequent virtual screening of a ZINC in-trial compound library identified 475 hits, which were advanced to molecular docking against the crystal structures of TOP1 (PDB: 1T8I) and TOP2A (PDB: 4FM9). This process yielded 15 top-ranked compounds with significantly superior predicted binding affinities compared to reference inhibitors. MM/GBSA refinement and systematic ADMET profiling further prioritized two in-silico candidate molecules ZINC13740825 and ZINC00586527 which exhibited robust binding free energies and favorable drug-like properties with low predicted toxicity. Quantitative structure-activity relationship (QSAR) models and Molecular Dynamics Simulation studies confirmed their potent predicted inhibitory activity and complex stability against both targets. These findings highlight the potential of these identified compounds as promising dual TOP1/TOP2A inhibitors for TNBC therapy, offering a strategic avenue to combat resistance mechanisms. Further experimental validation is warranted to translate these computational insights into therapeutic candidates.
- Open Access
- 13 November 2025
- Published by MDPI AG in Chemistry Proceedings
- Vol. 18 (1) , 8
Novel Chalcone Derivatives as Potent Lyn Tyrosine Kinase Inhibitors: A Promising In-Silico Approach for Targeted Therapy in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) accounts for approximately 10–15% of breast cancer cases and poses a significant clinical challenge due to its aggressive nature and poorer survival outcomes compared to other subtypes. This is primarily attributed to the lack of estrogen, progesterone, and HER2 receptors, which render conventional hormone-based therapies ineffective. In this study, we employed in silico approaches to design and evaluate novel chalcone derivatives as potential inhibitors of Lyn tyrosine kinase, a critical enzyme implicated in TNBC progression. The designed compounds were screened for drug-likeness and toxicity, all meeting Lipinski’s rule of five and demonstrating favorable toxicity profiles. Molecular docking analyses identified five promising ligands, CHCN1, CHCN19, CHCN48, CHCN333, and CHCN94, that exhibited comparable binding affinities to key active site residues of Lyn kinase, including Asp385, Phe386, Gly387, Lys275, and Glu290. Among these, CHCN1 showed the highest binding affinity at –8.4 kcal/mol, likely due to interactions with Asp385 and Lys275. These results suggest that the chalcone derivatives may effectively disrupt Lyn-mediated signaling pathways essential for cancer cell survival, potentially inhibiting proliferation, metastasis, and invasion. Overall, this study provides valuable insights into the therapeutic potential of chalcone derivatives for TNBC, offering promising avenues for targeted intervention.
- 13 November 2025
- Published by MDPI AG in Chemistry Proceedings
- Vol. 18 (1) , 8
Open AccessNovel Chalcone Derivatives as Potent Lyn Tyrosine Kinase Inhibitors: A Promising In-Silico Approach for Targeted Therapy in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) accounts for approximately 10–15% of breast cancer cases and poses a significant clinical challenge due to its aggressive nature and poorer survival outcomes compared to other subtypes. This is primarily attributed to the lack of estrogen, progesterone, and HER2 receptors, which render conventional hormone-based therapies ineffective. In this study, we employed in silico approaches to design and evaluate novel chalcone derivatives as potential inhibitors of Lyn tyrosine kinase, a critical enzyme implicated in TNBC progression. The designed compounds were screened for drug-likeness and toxicity, all meeting Lipinski’s rule of five and demonstrating favorable toxicity profiles. Molecular docking analyses identified five promising ligands, CHCN1, CHCN19, CHCN48, CHCN333, and CHCN94, that exhibited comparable binding affinities to key active site residues of Lyn kinase, including Asp385, Phe386, Gly387, Lys275, and Glu290. Among these, CHCN1 showed the highest binding affinity at –8.4 kcal/mol, likely due to interactions with Asp385 and Lys275. These results suggest that the chalcone derivatives may effectively disrupt Lyn-mediated signaling pathways essential for cancer cell survival, potentially inhibiting proliferation, metastasis, and invasion. Overall, this study provides valuable insights into the therapeutic potential of chalcone derivatives for TNBC, offering promising avenues for targeted intervention.